Test-and-treat for Influenza in Homeless Shelters

Phase 4TerminatedNCT04141917

University of Washington1,618 enrolled

Overview

This study is a stepped-wedge cluster-randomized trial of on-site rapid testing and treatment for influenza in homeless shelters within the Seattle area to determine whether this strategy reduced the incidence of influenza in the shelter environment.

The study will be conducted over the course of two flu seasons, and all shelters will start with routine surveillance of influenza using mid-turbinate nasal swabs for sample collection and RT-PCR testing. Shelters will be randomized to implement a test-and-treat strategy at different months throughout flu season, treating individuals who present ARI symptoms or new or worsening cough within 2 days (48 hours). Shelters will continue routine surveillance until all offer the test-and-treat strategy. Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment. Individuals with 3-7 days of symptoms, or who choose not to participate in the intervention strategy, will still be eligible for participation in the routine surveillance. Our primary hypothesis is that implementation of a point-of-care diagnostic and antiviral treatment intervention among sheltered individuals experiencing homelessness will reduce the incidence of influenza within this population over the course of a flu season. A process evaluation will also be conducted to explore the feasibility of point-of-care testing implementation in this population.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

1,618

Conditions

Influenza Respiratory Viral Infection

Interventions

Point-of-care molecular testing and treatment of influenzaCOMBINATION_PRODUCT

Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.

Eligibility

Sex: ALLMin age: 3 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Resident for 1 or more days at a participating shelter * ≥2 ARI symptoms or acute cough alone * Willing to take study medication * Willing to comply with all study procedures, including weekly surveillance and repeat nasal swab at day 2/3 and day 5/6/7 post-treatment * Able to provide written, informed consent and/or assent Exclusion Criteria: * Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration * Inability to consent and/or comply with study protocol * Individuals who have received oseltamivir or baloxavir within past 7 days for treatment of influenza * Individuals with known hypersensitivity to baloxavir marboxil or oseltamivir * Individuals with chronic kidney disease

Locations (9)

Mary's Place Burien

Burien, Washington, United States

Compass Housing Alliance at First Presbyterian

Seattle, Washington, United States

Downtown Emergency Service Center Shelter

Seattle, Washington, United States

Outcomes

Primary Outcomes

Number of Participants With Cases of Influenza in Shelters During the Intervention Period Compared to the Control Period

The intervention period is when test and treatment on-site was available and the control period is when just standard surveillance was available at a shelter.

Time frame: Year 1 of the intervention (4.5 months)

Secondary Outcomes

Feasibility of Implementation of Point-of-care Molecular Testing and Treatment of Influenza in Shelters

Number of participants/participant encounters with les than 48 hours between symptom onset until diagnosis with RT-PCR.

Time frame: Up to 24 months

Feasibility of Implementation of Influenza Treatment in Shelters

Number of influenza-positive participants identified through on-site molecular testing in the intervention period that were treated with an antiviral

Time frame: Up to 24 months

Number of Participants That Drop Out of Study

Measured as becoming lost to follow-up (did not complete both follow-up study visits on day 2/3 and day 5/6/7) after testing positive for influenza at baseline enrollment with an on-site molecular test and receiving an antiviral

Time frame: Up to 24 months

Number of Participants That Show Non-compliance With Study Drug

Only applicable to those that receive oseltamivir rather than baloxavir which is a single-dose antiviral. Measured based on self-report during follow-up visits with study research assistants. Non-compliance is measured as the participant self-reporting fewer doses taken than to be expected at time of of follow-up (e.g. a participant that took there first dose of oseltamivir in the AM on March 8 would be expected to have taken 6 doses if their follow-up visit was in the PM on March 10).

Time frame: Up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.